<DOC>
	<DOCNO>NCT00807794</DOCNO>
	<brief_summary>To evaluate clinical safety different dos MEDI-507 day 33 .</brief_summary>
	<brief_title>A Safety Clinical Trial Different Doses MEDI-507 Prevention Acute Renal Allograft Rejection</brief_title>
	<detailed_description>To evaluate pharmacokinetic characteristic MEDI-507 give dose interval .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Renal allograft recipient receive first second allograft Age 18 Maintained conventional immunosuppression Completed inform consent document Known hypersensitivity MEDI507 More two renal allograft Moribund unlikely ( opinion investigator ) survive duration trial Simultaneous use investigational agent ( include use licensed agent indication list package insert ) Any follow clinical setting diagnose posttransplant : pregnancy nurse mother : Ø Human Immunodeficiency Virus infection Ø hemodialysis chronic peritoneal dialysis Ø use ventilator Ø hyperacute rejection Having receive OKT3 , tacrolimus , antilymphocyte globulin current allograft Less 10 ml/hr average urine output 4 hour since end surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>